![]() ![]() We estimate the need to raise a total of £25m before turning EBITDA-positive in H225 and achieving net profitability in H126 (previously £30m and FY25, respectively).Ĭlick here to view the full report or here to sign up to receive research as it is published. Creo has developed CROMA, an electrosurgical Advanced Energy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. ![]() Development Bank of Wales and ACF Investors are the most recent investors. Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. Creo Medical is registered under the ticker LSE:CREO. Find company research, competitor information, contact details & financial data for CREO MEDICAL LIMITED of CHEPSTOW. Their latest funding was raised on from a Post-IPO Equity round. Our valuation is virtually unchanged at £493m or 272p/share after incorporating changes in our forecasts, including inclusion of ex-Europe consumables sales and the expected contribution from the Intuitive deal, partially offset by a more protracted ramp-up of the Speedboat Inject user base we now assume. Creo Medical has raised a total of 80.3M in funding over 4 rounds. We note that at current burn rates, Creo would need to raise funds by Q223 to continue supporting its development plans. We now categorise Creos revenue stream from three sources: Core technology, Consumables and Partnerships, resulting in our valuation rising to £493m or 272p/share, from £489m (269p/share) previously. ![]() To factor in these developments and the improved visibility of the companys near-term plans, we have revisited our model assumptions and introduced more granularity to our estimates. Creo Medical is a medical technology company transforming lives through the development and delivery of minimally invasive devices in the emerging field of. Enhanced levels of user, robotics deals with Intuitive and CMR, and multiple heads of terms agreements all suggest a potential inflection point for Creo. The period was marked by the increasing traction of Speedboat Inject (its flagship electrosurgical device) and its proprietary CROMA technology platform. The Companys mission is to improve patient outcomes by applying microwave and radiowave energy to surgical endoscopy. 2022 was an eventful year for Creo Medical, as it progressed on all fronts of its Build, Buy and Partner strategy. Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced. Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |